This bulletin provides information and resources to support deprescribing of these products which are considered low priority for prescribing and not cost-effective (with the exception of icosapent ethyl prescribed in line with NICE TA805).
Resources include data, audit, searches, patient information and an educational presentation.
Please login to view this content
Please login to view this content